Theravance Biopharma (TBPH) Interest Coverage Ratio (2016 - 2025)
Theravance Biopharma (TBPH) reported Interest Coverage Ratio of 34.38 for Q4 2025, up 340.32% year-over-year from 7.81 in Q4 2024, and up 405.23% quarter-over-quarter from 11.27 in Q3 2025.
Theravance Biopharma (TBPH) Interest Coverage Ratio (2016 - 2025) Analysis & Trends
Theravance Biopharma (TBPH) has 10 years of Interest Coverage Ratio data on file, last reported at 34.38 in Q4 2025.
- Interest Coverage Ratio for Q4 2025 came in at 34.38, up 340.32% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.74 (up 103.79% YoY), and the FY2025 annual result was 13.13, up 171.2% from the prior year.
- Interest Coverage Ratio grew to 34.38 in Q4 2025 per TBPH's latest filing, from 11.27 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 34.38 in Q4 2025 and troughed at 52.74 in Q4 2021.
- A 5-year average of 16.69 and a median of 15.79 in 2024 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2021 and 2025: Interest Coverage Ratio tumbled 1853.37% in 2021, then jumped 340.32% in 2025.
- A 5-year view of Interest Coverage Ratio shows it stood at 52.74 in 2021, then soared by 39.9% to 31.69 in 2022, then soared by 68.4% to 10.02 in 2023, then slumped by 42.85% to 14.31 in 2024, then soared by 340.32% to 34.38 in 2025.
- Business Quant data shows TBPH's Interest Coverage Ratio at 34.38 in Q4 2025, 11.27 in Q3 2025, and 4.11 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 3.58 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -258.33 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 11.50 |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 11.79 |
| 10 | Theravance Biopharma | 835.85 Mn | 441.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 34.38 |
| Sep 30, 2025 | -11.27 |
| Jun 30, 2025 | -4.11 |
| Mar 31, 2025 | -22.45 |
| Dec 31, 2024 | -14.31 |
| Sep 30, 2024 | -17.20 |
| Jun 30, 2024 | -24.39 |
| Mar 31, 2024 | -17.82 |
| Dec 31, 2023 | -10.02 |
| Sep 30, 2023 | -14.38 |
| Jun 30, 2023 | -28.39 |
| Mar 31, 2023 | -45.29 |
| Dec 31, 2022 | -31.69 |
| Sep 30, 2022 | -5.92 |
| Jun 30, 2022 | -12.58 |
| Mar 31, 2022 | -18.02 |
| Dec 31, 2021 | -52.74 |
| Sep 30, 2021 | -25.10 |
| Jun 30, 2021 | -5.52 |
| Mar 31, 2021 | -7.07 |